NRX Pharmaceuticals Inc Aktie News

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Company's Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Chief Financial Officer and Treasurer Conference Call Participants Tim Moore - EF Hutton Ed Woo - Ascendiant Capita...

2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor for an initial $7.5 million note, subject to common closing requirements, primarily to replace current debt, clearing the path to a Hope Therapeutics share distribution, with provision for fundi...

RADNOR, Pa. , May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.

RADNOR, Pa. , May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2024 financial results after the market closes on Tuesday, May 14, 2024, via press release, which will be available on the Company's website at  https://ir.nrxpharma.com/.

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic methodology memorialized in FDA Special Protocol Agreement.

NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076...

NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. NRX Pharmaceuticals is selling $2 million worth of NRXP stock for $3.30 per share in this offering.

The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter Four upcoming milestones expected: data from trials in Suicidal Bipolar Depression and Chronic Pain, NDA filing for IV Ketamine and distribution of shares of HOPE Therapeutics to existing shareholders Recent unanticipated achievements related to intravenous k...